Sign In
Buy OTLK
$0.98
-0.0634 (-6.10%)
At Close: Jul 31, 2026
Outlook Therapeutics encouraged by FDA acceptance of application for drug to treat retinal eye disease wet AMD
09:47am, Friday, 28'th Oct 2022
Outlook Therapeutics Inc (NASDAQ:OTLK) said the US Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for its investigational ophthalmic formulation of bevacizumab
Outlook Therapeutics enters into commercialization agreement with AmerisourceBergen
10:10am, Tuesday, 27'th Sep 2022
Outlook Therapeutics Inc (NASDAQ:OTLK) said it has entered into a strategic relationship with healthcare company AmerisourceBergen in preparation for the anticipated commercial launch in the United St
Outlook Therapeutics® to Present at Eyecelerator @ AAO 2022
08:35am, Monday, 26'th Sep 2022
ISELIN, N.J., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic f
Outlook Therapeutics® to Present at the H.C. Wainwright 24th Annual Global Investment Conference
08:05am, Wednesday, 07'th Sep 2022
ISELIN, N.J., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic f
Outlook Therapeutics re-submits biologics license application for ONS-5010 as a treatment for wet AMD to the FDA
09:49am, Tuesday, 30'th Aug 2022
Outlook Therapeutics Inc (NASDAQ:OTLK) said it has re-submitted its biologics license application (BLA) to the US Food and Drug Administration (FDA) for ONS-5010, an investigational ophthalmic therapy
Outlook Therapeutics strengthens board with appointment of ophthalmologist Dr Julia Haller
09:20am, Monday, 15'th Aug 2022
Outlook Therapeutics (NASDAQ:OTLK) Inc, a pre-commercial biopharmaceutical company working to develop the first US Food and Drug Administration (FDA)-approved ophthalmic formulation of bevacizumab for
Outlook Therapeutics ends 3Q with $26 million in cash and cash equivalents; plans to re-submit ONS-5010 application by September
10:01am, Wednesday, 10'th Aug 2022
Outlook Therapeutics (NASDAQ:OTLK) Inc said it ended the fiscal third quarter with $26 million in cash and cash equivalents that are expected to fund its work into the first calendar quarter of 2023
Outlook Therapeutics ends 3Q with $26 million in cash and cash equivalents; plans to re-submit ONS-5010 license application by September
09:57am, Wednesday, 10'th Aug 2022
Outlook Therapeutics (NASDAQ:OTLK) Inc has ended the fiscal third quarter with $26 million in cash and cash equivalents that are expected to fund its work into the first calendar quarter of 2023, in
Outlook Therapeutics confirms BLA re-submission date for its ONS-5010 wet AMD treatment
09:08am, Tuesday, 14'th Jun 2022
Outlook Therapeutics (NASDAQ:OTLK) Inc has provided an update on its Biologics License Application (BLA) submission for ONS-5010/LYTENAVA (bevacizumab-vikg) for the treatment of wet age-related macula
Outlook Therapeutics: A One-Buck Lottery Ticket
02:27pm, Thursday, 09'th Jun 2022
Today, we revisit Outlook Therapeutics for the first time since March 2021. The company recently temporarily withdrew its marketing application for its main asset, clouding the outlook on this small-c
Outlook Therapeutics opts to resubmit BLA for wet AMD drug after FDA requests more info
10:26am, Tuesday, 31'st May 2022
Outlook Therapeutics (NASDAQ:OTLK) Inc said it has voluntarily withdrawn the biologics license application (BLA) for its ophthalmic formulation of bevacizumab (ONS-5010 or Lytenava) after the US Food
Outlook Therapeutics to Present at the H.C. Wainwright Global Investment Conference
08:05am, Wednesday, 18'th May 2022
ISELIN, N.J., May 18, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic for
Outlook Therapeutics ends fiscal 2Q with $58.4M in cash as it ramps up pre-commercial activities for wet AMD treatment Lytenava
10:26am, Friday, 13'th May 2022
Outlook Therapeutics (NASDAQ:OTLK) Inc ended its fiscal second quarter with $58.4 million in cash – enough to launch its lead drug ONS-5010 without raising significant additional capital, it said. O
Outlook Therapeutics says its COO to talk wet AMD drug Lytenava at World Retina Conference this week
10:08am, Tuesday, 10'th May 2022
Outlook Therapeutics (NASDAQ:OTLK) Inc has said its chief operations officer Terry Dagnon will discuss the company's wet age-related macular degeneration (AMD) drug Lytenava as part of a panel at the
Outlook Therapeutics says BioLexis reorganization results in GMS Holdings becoming its largest shareholder
09:36am, Friday, 22'nd Apr 2022
Outlook Therapeutics (NASDAQ:OTLK) Inc revealed that BioLexis Private Limited, a strategic shareholder in the pre-commercial biopharmaceutical company, is being reorganized and has resulted in GMS Hol
